Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Regulation and Oncology Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DAXX drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant DAXX Protein (Functional Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. |
View DAXX Products |
| Gene Delivery | DAXX Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View DAXX Products |
| Benchmark Ab | Anti-DAXX Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View DAXX Products |
| Validator | DAXX siRNA Set Target-specific knockdown verification in cancer cell lines. |
View DAXX Products |
| Related Target A | ATRX Chaperone partner forming the DAXX-ATRX complex for histone H3.3 deposition. |
View ATRX Products |
| Related Target B | H3F3A (Histone H3.3) Specific histone client of the DAXX chaperone complex, critical for chromatin deposition assays. |
View H3F3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screen (DAXX-ATRX / DAXX-H3.3) | High-purity recombinant domains with native-like folding and sequence verification. |
| Target Specificity & Off-target Screening | Homolog and partner panels (ATRX, H3.3, H3.1) strictly verified by Mass Spectrometry. |
| Lack of Validated Controls | Sequence-defined recombinant antibodies and reference biosimilars included. |
| False Positives in Knockdown Studies | Sequence-verified, multi-target siRNA pools for robust target validation. |
Live DAXX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DAXX therapeutics is intensifying, with major players shifting focus from traditional chromatin biology research to targeted epigenetic therapeutics. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting the disruption of the DAXX-ATRX complex and the degradation of DAXX via PROTACs to treat pancreatic neuroendocrine tumors (pNETs), glioblastomas, and therapy-resistant prostate cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Biotech Startups, Academic Consortia | pNETs, Glioblastoma, AML | High-throughput screening assays (Need sequence-verified DAXX folded domains) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Companies | Prostate Cancer, Ovarian Cancer | Ubiquitination & degradation assays (Need Lentivirus for stable cell lines) |
| Combination Therapies | Oncology-focused Pharma | Refractory Solid Tumors | Synergy validation (Need ATRX and H3F3A target controls) |